Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428880 | 0.74 | ALDH1A1 (0.34) | GAAHTTPAX8MEN1KMT2A | |
| SCHEMBL4488975 | 0.69 | ABCB1 (0.33) | — | |
| SCHEMBL163425 | 0.68 | MEN1 (0.41) | GAAHTTPAX8MEN1KMT2A | |
| SCHEMBL2867325 | 0.68 | MEN1 (0.41) | GAAHTTPAX8MEN1KMT2A | |
| SCHEMBL15357343 | 0.66 | — | — | |
| SCHEMBL19455945 | 0.66 | — | — | |
| SCHEMBL14952771 | 0.64 | MEN1 (0.36) | GAAHTTPAX8MEN1KMT2A | |
| SCHEMBL20734815 | 0.64 | MAOB (0.36) | MEN1KMT2A | |
| SCHEMBL20734816 | 0.64 | MAOB (0.36) | MEN1KMT2A | |
| SCHEMBL14952819 | 0.63 | MLNR (0.48) | GAAKMT2AALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011589-B2 | Treatments for gastrointestinal conditions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-07-03 | — | — | US | disclosed |
| US-10011589-B2 | Treatments for gastrointestinal conditions | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170073332-A1 | Treatments for Gastrointestinal Conditions | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073332-A1 | Treatments for Gastrointestinal Conditions | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-3116499-A1 | TREATMENTS FOR GASTROINTESTINAL CONDITIONS | Board of Regents, The University of Texas System (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138753-A1 | TREATMENTS FOR GASTROINTESTINAL CONDITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011589-B2 | Treatments for gastrointestinal conditions | SI, FABP2, SLC10A2 | GAA 67/4885HTT 886/4885PAX8 4684/4885 |
| US-20170073332-A1 | Treatments for Gastrointestinal Conditions | SI, FABP2, SLC10A2 | GAA 67/4885HTT 886/4885PAX8 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.